ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0746

Application of Existing Patient-Reported Outcome Measures for Telehealth Encounters: What’s Feasible?

Patricia Katz1, Meera Subash1, Martin Bergman2 and Kaleb Michaud3, 1University of California San Francisco, San Francisco, CA, 2Martin Jan Bergman, MD, Ridley Park, PA, 3University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2021

Keywords: Patient reported outcomes, telemedicine

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Measurements (0739–0763)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Validated patient-reported outcome (PRO) measures play important roles in assessing and managing of patients with rheumatic diseases. However, use of these validated scales may not be feasible in the setting of telehealth encounters. Likewise, completion of physician-reported measures of disease activity may not be possible via telehealth because, for example, joint examinations and global assessments cannot be conducted reliably. In both cases, acceptable proxies are needed for use in telehealth as this method of care delivery remains widely used. We examined the relationship between (1) simple, single-item ratings of pain, function, and fatigue with validated scales measuring the same constructs, and (2) patient and physician ratings of disease activity in patients with rheumatoid arthritis.

Methods: Analysis 1 uses data from FORWARD, The National Databank for Rheumatic Diseases, a longitudinal registry of individuals with rheumatic diseases. Data are regularly collected via semi-annual questionnaires. Within each questionnaire, pain, function, and fatigue are assessed by both single-items and validated scales (Table 1). Spearman correlations examine the associations between single-item and scales for each construct at 4 different questionnaire administrations and between 6-month changes in item and scale responses. Analyses were conducted separately for rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and osteoarthritis (OA). Analysis 2 uses data from a study of people with rheumatoid arthritis in which both the Clinical Disease Activity Index (CDAI) and patient-reported Rheumatoid Arthritis Disease Activity Index (RADAI) were completed. Spearman correlations examine associations between CDAI and RADAI scores and components (global assessments, joint counts).

Results: Analysis 1: Participants with RA (n=7478) had mean age 68±11 years, were 92% white and 83% female; those with SLE (n=893) had mean age 63± 13 years, were 83% white, and 94% female; and those with OA (n=3371) had mean age 70± 10 years, were 95% white, and 86% female. Cross-sectional correlations between single items and scales were uniformly medium to large (Table 1). Correlations between change scores, however, were small (Table 2)..

Analysis 2: Participants (n=48) had mean age 58 ± 12 years, were 76% female, 36% white, 7% Asian, 14% Black, and 43% other/multi-racial, and 36% LatinX ethnicity. Correlations between CDAI and RADAI total scores was 0.70, RADAI painful joint count and CDAI tender joints 0.71, and RADAI and CDAI global assessments 0.57.

Conclusion: Cross-sectional group associations between single-item and scale responses were high suggesting the potential for usefulness in telehealth settings where rheumatologists may not have sufficient time to complete longer validated measures nor data from a physical exam. Correlations in changes, however, were low, perhaps reflecting reduced precision of the single-item measures, which might limit the usefulness of these measures for following patients over time. The moderate-high associations between CDAI and RADAI scores and components suggests that remote patient-completed assessments of disease activity may be useful in telehealth settings.


Disclosures: P. Katz, None; M. Subash, None; M. Bergman, AbbVie, 2, 6, Amgen Inc., 6, Novartis, 2, 6, Pfizer, 2, 6, Sanofi, 2, 6, Bristol Myers Squibb, 2, Celgene, 2, Genentech, 2, Janssen, 2, Merck, 2, Johnson & Johnson, 11, Sandoz, 1, GSK, 6, Scipher, 2; K. Michaud, None.

To cite this abstract in AMA style:

Katz P, Subash M, Bergman M, Michaud K. Application of Existing Patient-Reported Outcome Measures for Telehealth Encounters: What’s Feasible? [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/application-of-existing-patient-reported-outcome-measures-for-telehealth-encounters-whats-feasible/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/application-of-existing-patient-reported-outcome-measures-for-telehealth-encounters-whats-feasible/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology